|Home-- -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- -Contact|
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development
The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding has the potential to improve both the safety and performance of reprogrammed cells.
The researchers' study, published in the journal Nature, found that an enzyme, activation-induced cytidine deaminase (AID), helps in the process that changes an adult human cell into an induced pluripotent stem cell (iPS cell). These iPS cells can then be developed into any kind of cell needed to therapeutically restore tissues and organs.
The finding settles an ongoing controversy regarding use of AID to reprogram cells, says the study's senior investigator, Dr. Todd Evans, vice chair for research and professor of cell and developmental biology in the Department of Surgery at Weill Cornell Medical College.
"The dispute was whether AID is required to make iPS cells, and we found that the enzyme does make reprogramming very efficient, although it is not absolutely necessary," says Dr. Evans, an internationally-recognized authority on regenerative medicine. "In fact, we plan to test if reprogramming iPS cells without AID may even be helpful."
One reason is that AID can cause genetic mutations that can lead to cancer.
AID is best known as a master regulator of antibody diversity in B cells, and in order to create varied types of beneficial antibodies, it routinely mutates antibody genes. But sometimes the process goes awry, resulting in development of B cell lymphoma.
"That leads us to believe that if you can reprogram cells without AID, it could reduce risk of potential mutations, and thus be safer."
Dr. Todd Evans, vice chair for research and professor of cell and developmental biology in the Department of Surgery at Weill Cornell Medical College.
iPS Cells Without AID Remember What They Once Were
In order to push a cell such as a fibroblast back to an iPS cell, the "epigenetic markers" that define the adult cell must be removed. Dr. Evans: "All cells of the body have the same genes, but they are used differently in different tissues. If an undifferentiated cell becomes a heart cell, somehow it has to lock in and stabilize that particular adult phenotype and not forget what it is."
One way this is accomplished is by placing a methyl group on top of specific genes to activate a new cell destination—such as to become a liver cell—usually switching the previous gene destination off. "We have known how these marks are put on genes, but we didn't know how they were taken off. This is the process of pushing an adult cell to revert back to a stem-cell-like state," Dr. Evans says.
Dr. Evans and his colleagues found that the AID (activation-induced cytidine deaminase) enzyme removes epigenetic markers.
They then created a mouse that did not produce AID to see if the animal's adult fibroblast cells could be pushed back to iPS cells. Surprisingly, they found that the cells at first seemed to want to reprogram even faster than normal cells, but most never fully reverted to a stem-cell-like state. Dr. Evans: "They eventually crashed and differentiated back into a fibroblast. What that meant is that they never cleared their memory of being a fibroblast cell. AID efficiently removes that epigenetic memory, smoothing the way for a cell to morph into an undifferentiated state."
But some of the mouse adult fibroblasts lacking AID—those that Dr. Evans says they "babysat"—did become iPS cells.
Despite the fact that reprogramming adult cells without AID is inefficient, the researchers say that the method may offer another advantage besides increased safety. Dr. Evans : "It might be useful to allow epigenetic memory to be retained. If you want to make new cardiac cells to repair a patient's heart, it might be better to start with a cardiac cell and push it to become an iPS cell, from which other cardiac cells could be made. If these cells remember they were cardiac cells, they might make a better heart cell than if they came from reprogrammed fibroblasts."
The study was supported by National Institutes of Health grants (HL056182 and AI072194) and a National Science Foundation CAREER grant (1054964).
Other study co-authors include Ritu Kumar, Ting-Chun Liu, Philipp Franck and Olivier Elemento from Weill Cornell Medical College; Lauren DiMenna, Nadine Schrode, Silvia Muñoz-Descalzo, Anna-Katerina Hadjantonakis and Jayanta Chaudhuri from Memorial Sloan-Kettering Cancer Institute; and Ali A. Zarrin from Genentech.
The authors declare no competing financial interests.
Weill Cornell Medical College
Original press release:http://www.eurekalert.org/pub_releases/2013-08/wcmc-air080113.php